Innovating Bispecific Antibody Development at Amgen
This application note describes a new workflow designed at Amgen for the development of bispecific antibody therapeutics. In this workflow, scientists analyzed high-throughput binding data using Genedata Screener®, enabling them to:
- Rapidly identify, using automated analysis of high-volume data, rare bispecific molecules with promising properties for further development.
- Ensure consistent analysis using built-in business logic and pre-defined processing parameters to automate fitting and result derivation.
- Easily share results via reliable reporting to the data warehouse or reports containing key result values and raw data traces.
Learn more about using Screener to analyze large molecule assays here.